News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Paul M. Howell, BS

Articles by Paul M. Howell, BS

Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma

ByAdam I. Riker, MD,Paul M. Howell, BS

March 12th 2011

Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade

Latest Updated Articles

$Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma$
Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma
March 12th 2011

Trending on OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC

GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates